Research Article

Biomarkers for Predicting Left Atrial or Left Atrial Appendage Thrombus in Anticoagulated Patients with Nonvalvular Atrial Fibrillation

Table 1

Baseline characteristics of NVAF patients with or without thrombus and SEC.

VariableNo thrombus group (n = 84)SEC group (n = 131)Thrombus group (n = 45) value

Age (years)62.58 ± 10.1264.41 ± 8.4263.56 ± 10.610.379
Male51 (60.7)74 (56.5)27 (60)0.807
Smoking history18 (21.4)36 (27.5)17 (37.8)0.139
Drinking history13 (15.5)15 (11.5)10 (22.2)0.203
History of coronary heart disease37 (44.0)47 (35.9)16 (35.6)0.441
After PCI10 (11.9)14 (10.7)4 (8.9)0.870
Old myocardial infarction3 (3.6)4 (3.1)1 (2.2)0.914
Hypertension51 (60.7)77 (58.8)23 (51.1)0.559
Diabetes mellitus16 (19.0)27 (20.6)10 (22.2)0.909
Stroke/TIA11 (13.1)18 (13.7)19 (20)0.527
Paroxysmal AF66 (78.6)65 (49.6)23 (46.7)<0.001
CHA2DS2-VASc score2.20 ± 1.632.19 ± 1.602.20 ± 1.710.630
CHA2DS2-VASc score ≥253 (63.1)81 (61.8)26 (57.8)0.835
Recurrent AF after ablation8 (9.5)11 (8.4)2 (4.4)0.590

AF = atrial fibrillation; TIA = transient ischemic attack; CHA2DS2-VASc = congestive heart failure, hypertension, age, diabetes mellitus, stroke, vascular disease, and sex. vs. no thrombus group.